Biotech "Tweets of the Week"
Mr. Shkreli Goes to Washington
(February 1-5, 2016)
Featuring:
$AAVL $ACAD $ADAP $AGN $AVXS $AXON $BGNE $BLUE $CEMP $EDIT $GILD $ICPT $JUNO $KITE $ONCE $PETX $PFE $PTI $SRPT $VRTX $VRX $XBI $IBB
FDA, biosimilars, drug pricing, opioids, biotech market sentiment, cancer moon shot, CRISPR, IPOs
Looking for past biotech highlights? Check out the Biotech Tweets of the Week archive.
IPO window opens for Editas, others $EDIT $BGNE $PTI $AVXS
If this was a year ago, Annapurna probably could have IPO’d at a huge valuation. $AAVL
— Brad Loncar (@bradloncar) February 1, 2016
Proteostasis, AveXis price #IPO's amid drought of offerings https://t.co/VWDHeYDtjF $PTI $AVXS #biotech
— Bio Stocks™ (@BioStocks) February 1, 2016
This excellent review of $EDIT’s IPO roadshow hasn’t gotten nearly enough attention https://t.co/Ep8meMjSE9
— Arsalan Arif (@AKAarsalan) February 1, 2016
$EDIT IPO status, via my buyside source, talking to i-bank:
— Adam Feuerstein (@adamfeuerstein) February 1, 2016
Demand: “good mix” x-over funds, MFs > HFs. Over-subscribed.
Price: In range.
$ONCE vs $EDIT: $325M MC Ph3 at IPO vs $600M MC clinic in 2017 at IPO. FYI.
— Michael Torres, PhD (@Mykalt45) February 2, 2016
$BGNE Beigene #IPO prices upsized 6.6M shares at $24, top end of planned range --> ~$800M mkt cap pic.twitter.com/f13WaSWbee
— Andy Biotech (@AndyBiotech) February 3, 2016
BioCentury wrote Editas' post-money valuation, $571.2M, is thehighest of any preclinical biotech IPO since '94 https://t.co/57aTyGFmTT $EDIT
— Pearl Freier (@PearlF) February 3, 2016
I suspect the only reason for $EDIT to go public now before clarity on the IP is for the VC's to have a chance to exit before a decision
— Maxim Jacobs, CFA (@MaxJacobsEdison) February 2, 2016
@CGrantWSJ $EDIT second $AXON IPO
— Tom Silver (@TomSilver39) February 3, 2016
Two biotech IPOs make it out "in the range" despite mkt volatility. Congrats to both $EDIT and $BGNE. Hope they trade well in aftermarket.
— Bruce Booth (@LifeSciVC) February 3, 2016
It'll suck short term for the sector if $EDIT can't hold the IPO price this week and into the next.
— David Miller (@AlpineBV_Miller) February 3, 2016
Caveat emptor $BGNE ADS holders: You are not real shareholders;you do not have BoD representation &you will probably be screwed at some pt.
— Roy Friedman (@DewDiligence) February 3, 2016
.@LifeSciVC certainly can't hurt the queue, although a buysider just told me anyone but $EDIT and $BGNE "would be crazy to try to go out."
— Steven Edelson (@StevenEdelson) February 4, 2016
2 biotech IPOs postponed this morn, according to @Drew_Singer
— Sasha Damouni Ellis (@SashaDamouni) February 4, 2016
PLX Pharma & Therapure Biopharma Said to Postpone IPOs on Market Conditions
Gilead earnings and outlook draw usual scrutiny $GILD
@AndyBiotech So $GILD says biotech valuations still too high ?
— BioStockAddict (@BioStockAddict) February 1, 2016
Whoa --> MT @Dougallan1: $mrk wins infringement claim against $gild over Sovaldi/Harvonipic.twitter.com/wKe54ASmFO
— Andy Biotech (@AndyBiotech) February 2, 2016
I asked investor sources, “Is there anything $GILD can report or say tonight to make the stock go up?”
— Adam Feuerstein (@adamfeuerstein) February 2, 2016
The collective response: “No."
Thank you $gild
— Douglas Allan (@Dougallan1) February 2, 2016
FYI, $GILD has enough cash flow to do a buyback and M&A. The idea that they are mutually exclusive is a false dichotomy.
— David Sobek (@dsobek) February 2, 2016
"There’s a line out the door of patients that need to be treated that are accessible," $GILD says on conference call.
— Meg Tirrell (@megtirrell) February 2, 2016
$GILD new CEO John Milligan says he's got a shopping list in his mind of potential M&A targets, if "right opp at right price" comes along
— Meg Tirrell (@megtirrell) February 2, 2016
$GILD CC: No. of untreated,DIAGNOSED HCV patients decreasing *very slowly* despite high Tx rate b/c many new Dx's. Not a cliff!! $ABBV $ENTA
— Roy Friedman (@DewDiligence) February 2, 2016
$GILD PT lowered to $114 from $134 at Piper
— Bio Stocks™ (@BioStocks) February 3, 2016
$GILD : Most Valuable Biotech Asset in Market is Our Own Stock https://t.co/P1u9el8uUH But M&A not off table completely.
— Adam Feuerstein (@adamfeuerstein) February 3, 2016
. @sharkbiotech On other hand, folks prefer earnings accretion via top-line growth. Buybacks tacit acknowledgement it can’t be done. $GILD
— Adam Feuerstein (@adamfeuerstein) February 3, 2016
Martin Shkreli and Turing grilled by Congress $VRX
*MARTIN SHKRELI'S LAWYER SAYS HE WILL BE IN WASHINGTON THURSDAY
— Drew Armstrong (@ArmstrongDrew) February 3, 2016
Here we go...
"It's not funny Mr. Shkreli. People are dying and they are getting sicker and sicker." Cummings, looking down toward the audience.
— Matthew Herper (@matthewherper) February 4, 2016
Shkreli:
— Meg Tirrell (@megtirrell) February 4, 2016
"On the advice of counsel I will not be giving an opening statement."
"On the advice of counsel I invoke the 5th amendment."
"Wholesale list price of a drug is not the same as the price paid by pts, hospitals, health plans or govt programs," Turing's Retzlaff says
— Meg Tirrell (@megtirrell) February 4, 2016
And now, we will have the Congressional hearing on unnecessary testing procedures and high costs within hospital systems...oh...wait....
— Dan Budwick (@DanBudwick) February 4, 2016
What happened today: a group of politicians created media snippets for their re-election campaigns. @adamfeuerstein @matthewherper
— Bob More (@Bobmorevc) February 4, 2016
If I were a Turing investor I might favor making Nancy Retzlaff CEO. She did very well in front of a hostile Congress.
— Matthew Herper (@matthewherper) February 4, 2016
You've got to be kidding me. Shkreli's lawyer just told @CNBCClosingBell his client is "a scientist" and "he's saving lives".
— Mike Huckman (@MikeHuckman) February 4, 2016
Shkreli's lawyer calls tweet after hearing "unfortunate." It's regrettable choice of words."
— Drew Armstrong (@ArmstrongDrew) February 4, 2016
Comments from FDA leadership on generics, biosimilars, and opioids
NOW: Dr. Woodcock testifying to #HOGR on #drugprices and #genericdrugs. #FDAHearing
— FDA Drug Information (@FDA_Drug_Info) February 4, 2016
Woodcock explaining that for a small segment of generic drugs there is no competition. Daraprim has nothing to do with the backlog.
— Matthew Herper (@matthewherper) February 4, 2016
Interesting data point from @US_FDA 's Woodcock: 10% of drugs in the U.S. aren't patent protected but lack generic
— Jonathan Rockoff (@jonathanrockoff) February 4, 2016
Woodcock: 125 innovator drugs with no patent or exclusivity. Price hikes are not the result of FDA’s backlog. No one is sending in ANDAs
— Zach Brennan (@ZacharyBrennan) February 4, 2016
@JohnTuckerPhD Woodock made clear last week that there are zero.
— Zach Brennan (@ZacharyBrennan) February 4, 2016
Woodock says FDA MAY approve a biosimilar as interchangeable without issuing guidance on what interchangeability means.
— Zach Brennan (@ZacharyBrennan) February 4, 2016
Janet Woodcock explaining to Congress that companies make shit up. Somehow, this is a surprise.
— Matthew Herper (@matthewherper) February 4, 2016
Chaffetz presses FDA on abuse of priority review vouchers. Woodcock agrees they are diverting FDA resources but says Congress created system
— Brenda Sandburg (@brendasandburg) February 4, 2016
As seen on the stream
BREAKING: UK approves gene-editing technique to fight diseases; critics say move crosses ethical lines
— The Associated Press (@AP) February 1, 2016
Sun Pharma launched generic gleevec
— NathanAaron (@NathanAhron) February 1, 2016
$AAVL and Annapurna Therapeutics Announce Proposed Mergerhttps://t.co/MIEdWdk91n
— Bio Stocks™ (@BioStocks) February 1, 2016
@rhmconsultants Nobody is buying $MSTX. I know, because I'm trying to sell it.
— Tony Friedman (@zzlangerhans) February 1, 2016
Last may $ESPR was 120. wow. I know there are many similar stories, but I remember many averaging down about 3 times higher than here
— DeadCatBill (@getbillasap) February 1, 2016
My top Bios: $SRPT $GILD $RLYP
— John Hall (@johnhallnj) February 1, 2016
January was not kind to me.
Not sure a stock can trade worse into potential data than what $CLDX has been doing.
— Brad Loncar (@bradloncar) February 1, 2016
$IBB $XBI biotech still among the weakest, flows... agree that only M&A could take it out of it's misery, no sign so far.
— Jean Fonteneau (@JFinDallas) February 1, 2016
@PRB51 @stanleydandrea @matthewherper 'Hostile takeovers' are expected in every downturn, but they are almost never seen.
— David Miller (@AlpineBV_Miller) February 1, 2016
$IBB If the groundhog sees his shadow tomorrow - 6 more weeks of selling?
— Red Acre Investments (@redacre) February 1, 2016
$RLYP slowly accumulating Feb puts.. I hope it will be money thrown in the incinerator but covering my butt just in case
— Tony (@tony__teo) February 1, 2016
Think there's too much skepticism of this cancer moonshot thing. By Washington standards, it's actually not off to a bad start.
— Brad Loncar (@bradloncar) February 1, 2016
Drug price growth, from @Altarum https://t.co/ihBVuPnVFS pic.twitter.com/PmhcQ2Is8c
— Austin Frakt (@afrakt) February 2, 2016
$CEMP 18.01
— Tom Wrigley (@WrigleyTom) February 5, 2016
The Lancet Infectious Diseases Publishes Positive
Phase 3 Study Results for Cempra’s Oral Solithr...https://t.co/P9yGh0MU04
$AGN showing some relative strength
— HumbleBioTrader (@HumbleBioTrader) February 2, 2016
$PFE CEO Ian Read: "Under current law, I do not believe there is any reason why this deal will not close. Full stop." $AGN
— Meg Tirrell (@megtirrell) February 2, 2016
Covered $neos 10.51 from 13.04
— DeadCatBill (@getbillasap) February 2, 2016
$GSK and $ADAP deal expansion includes cost-sharing in up to 8 combination therapies with 3rd parties - starting in H2 2016 !
— Dieter Hovekamp (@dhovekamp42) February 2, 2016
.@psuvafan007 CRISPR won't fix anything if you can't get it into the target cell.
— Garrett Rhyasen (@MrStemCell) February 2, 2016
.@lisamjarvis' annual story on new drug approvals is always a great read!https://t.co/MMt2L57M4l pic.twitter.com/eWkkqtp6MS
— Andy Biotech (@AndyBiotech) February 2, 2016
$HNSN FDA approval of MagellanRobotic Catheter... pretty sure that approval didn't leak yesterday with the stock up 50%.
— Shane Blackmon (@shaneblackmon) February 2, 2016
All these beats and nothing.
— Michael Torres, PhD (@Mykalt45) February 2, 2016
$AXON -16% on $PFE 5HT6 trial termination.
— Adam Feuerstein (@adamfeuerstein) February 2, 2016
Feb2016 BeatDown Bios: $CBAY $CPXX $CPRX $PIRS $SYN $ONTY $ATNM $AVEO $CTIC $CRBP $IMNP $BCLI $SPHS $VSTM $PLX $CERU $CNAT $APRI $RTTR $NEOT
— Sheff (@SheffStation) February 2, 2016
@stanleydandrea @bradloncar That's why they need to address the first part rather than just the second part, otherwise issue not going away.
— JQ (@jq1234t) February 2, 2016
$JUNO Fresh new all-time lows today. Once, an IPO darling.
— TurboResearch (@TurboResearch) February 2, 2016
.@GKButterfield @SusanWBrooks want to add #Zika to #FDA tropical disease priority review voucher programhttps://t.co/TBXZAUKz1s #ZikaVirus
— Donna Young (@ScripDonnaDC) February 2, 2016
Valeant’s Sales Growth: Driven by Price Increases or Volume Growth? https://t.co/MiSyCP9NjN $VRX
— PropThink (@PropThinker) February 2, 2016
Sell side doing backflips to avoid "lied."
$XBI new lows... broke last weeks low. Biotech bloodbath continues in 2016
— Shane Blackmon (@shaneblackmon) February 2, 2016
Let's make this viral, folks -- #JPM16
— John Carroll (@JohnCFierce) February 2, 2016
'Let this letter be a shot across the bow to the entire industry'https://t.co/ec4VUhvdxL
Everyone talking about M&A but I think what biotech needs is good data.Gene tx slowing down, CAR-T still in dev, HepB & NASH disappointing..
— Jordi Xiol (@jordixiol) February 2, 2016
@JoeP450 @megtirrell interesting that despite $icpt BO chatter today, stock finished down 10%. Tells you no one is buying hype in #biotech
— Joe (@Drchik23) February 3, 2016
$CLVS $ACAD became teenagers today #biotech #BearMarket
— Dan Rosenblum (@sharkbiotech) February 3, 2016
BioPharmCatalyst updates: $BNHLF expected CRL. $SYN Ph2 trial fail. $ARRY Phase 3 data due 2016 + $MDWD $NBIX $HSGX https://t.co/5eYxJqRRC6
— BioPharmCatalyst (@crusadernz) February 3, 2016
$BLUE Leerink initiates w/ outperform $67 PT.
— Adam Feuerstein (@adamfeuerstein) February 3, 2016
Oh, how things have changed….
On the topic of persistence and durability, Carl June says the first patient he treated in 2010 still has CART cells in his body. #IO360nyc
— Brad Loncar (@bradloncar) February 3, 2016
$LABD flying..
— E B (@Mazmasta) February 3, 2016
#biotech selling is in the "get me out I dont care" phase now
— Dan Rosenblum (@sharkbiotech) February 3, 2016
By my calculation biopharma valuations fell $644bn in January. Via @EPVantage https://t.co/b6RUtalK3E $SRPT $OMED $GILD $PBYI $BLCM
— Jacob Plieth (@JacobPlieth) February 3, 2016
$ACAD could have conducted the 2nd, confirmatory ph3 study of pimavanserin in time it took to get the NDA filed. Interesting (to me.)
— Adam Feuerstein (@adamfeuerstein) February 3, 2016
Sentiment running at such extreme negative for biotech/healthcare that even I am starting to think some dead cat is at hand.. $IBB $XBI $XLV
— Jean Fonteneau (@JFinDallas) February 3, 2016
.@BuyersStrike I'm not trading these days, pure wait and see. Like some names but still see a lot of overvalued biotechs
— Juan P. Serrate, DVM (@JPZaragoza1) February 3, 2016
Hard to trust the markets
— Raj R (@rajramaswamy) February 3, 2016
Clearing the Body's Retired Cells Slows Aging, Extends Life https://t.co/qv2m1EtMdF [h/t @edyong209]
— ENDPOINTS (@endpts) February 3, 2016
Part of the cancer moonshot funding should go towards educating people that cancer is not one disease.
— Brad Loncar (@bradloncar) February 3, 2016
$ONCE a 20% intraday move on technically no news (other than the $EDIT IPO, which was uneventful). Baby it's weird out there.
— Cody (@codytrades) February 3, 2016
ASH pays Apple more than AASLD? "hepatology" autocorrects to "hematology". Who knew...
— Ethan Weiss (@ethanjweiss) February 3, 2016
@shaneblackmon a crowded trade never stays that way...
— btc (@anniebtc) February 3, 2016
Things collapsing in unison: #yuan #biotech #oil #commodities #euro #$tsla #USpolitics #drugprices #junkbonds #stocks #mytwitterfeed
— Joe (@Drchik23) February 4, 2016
CS with a bunch of animal health initiations $ZTS $PETS $IDXX $PETX $NVET
— j l (@bio_clouseau) February 4, 2016
$PETX AT005 received full approval yday - now have 2 of 3 full USDA/FDA approved drugs to meet covenant. On track for 6 approvals by end '16
— Zack (@BioTerp) February 4, 2016
#Biotech stock trading in a (very) down market: lessons from the when the market was hot. https://t.co/jBdSdGTvmH pic.twitter.com/8oAUCbDCss
— David Sable (@dbsable) February 4, 2016
$BIIB disclosed in 10-K that it received a subpoena from the federal government for documents relating to its relationship with certain PBMs
— Andy Biotech (@AndyBiotech) February 4, 2016
$blue ccald data in april, new bthal patient showing promise, megatal gene editing, some success with scd, MM car-t enrolling
— Joshua B (@srqstockpicker) February 4, 2016
$LABU up 31% from yesterday's bottom. Why scan for stocks to day trade when you can just daytrade $LABU/$LABD?
— BioBounce.com (@BioBounce) February 4, 2016
Embattled Theranos has job listing for writer who “can solve problems through the power of excellent storytelling.” https://t.co/DQ4oghKFUr
— Sarah Kliff (@sarahkliff) February 4, 2016
.@23aloha We knew there would be a relief rally after the drug price hearing concluded but these jumps shows how big the overhang really was
— David Maizenberg (@biologypartners) February 4, 2016
Feb2016 BeatDown Bios: $CBAY $CPXX $CPRX $PIRS $SYN $ONTY $ATNM $AVEO $CTIC $CRBP $IMNP $BCLI $SPHS $VSTM $PLX $CERU $CNAT $APRI $RTTR $NEOT
— Sheff (@SheffStation) February 2, 2016
@TheBio_Hunter that why when I hear "going long this stock" I kind of wince. Good profits need to be taken sooner rather than later IMO.
— Sheff (@SheffStation) February 4, 2016
FDA trying to ease Califf's pain, Markey and Manchin continue to block Califf's confirmation https://t.co/gB9gadxiuT
— JQ (@jq1234t) February 5, 2016
$CEMP 18.01
— Tom Wrigley (@WrigleyTom) February 5, 2016
The Lancet Infectious Diseases Publishes Positive
Phase 3 Study Results for Cempra’s Oral Solithr...https://t.co/P9yGh0MU04
#FDA Celltrion infliximab #biosimilar adcomm docs uphttps://t.co/95V71BG4RV $JNJ #pharma #biosimilars #biotech
— Donna Young (@ScripDonnaDC) February 5, 2016
Cowen $HRTX FDA Aims To Fight Opioid Abuse, Positive For Alternatives Such As HTX-011 target 40
— dough (@tgtxdough) February 5, 2016
Oops $VRTX CRL
— j l (@bio_clouseau) February 5, 2016
$VRTX CRL... Potential upside to 2016 guidance gone...https://t.co/7bcNCI5iWO
— Andy Biotech (@AndyBiotech) February 5, 2016
$BOTA $57.2 mil cash Dec 31. HRV and RSV programs on track for H2 2016 readouts. BTA074 P2 patient screening started https://t.co/1Y0rE826RJ
— Daniel Ward (@danwardbio) February 5, 2016
$fgen added few here at 17.1
— Pharmd (@Pharmdca) February 5, 2016
New biotech market: 2.5% drop in the IBB elicits barely a mention.
— Charley Grant (@CGrantWSJ) February 5, 2016
Despite the $XBI dropping 2.5% $SRPT is going from Red to Green with huge bet on Mar $16 where 4,894 calls bought today on 65 Open Interest
— Joe (@GantosJ) February 5, 2016
Breaking: Theranos says it has an extension from CMS to respond to audit report -- story with @ZTracer on @business terminal.
— Caroline Chen (@CarolineYLChen) February 5, 2016
BiotechDueDiligence marked its 5-yr anniversary recently. A little blog has turned into so much more, thanks to all supporters new and old!
— Andrew G. (@BioDueDiligence) February 5, 2016